louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06467019: Informative Exhibition for Deprescribing Benzodiazepines
Official title: Impact of an Interactive and Informative Exhibition on Benzodiazepine Use on Deprescription.
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Benzodiazepine-Related Disorders
Keywords: Benzodiazepines
Deprescriptions
Lead sponsor: Consorci Sanitari de l'Alt Penedès i Garraf
Sponsor class: OTHER
First posted: 2024-06-20
Enrollment: 6410
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community population assigned to a primary care center.

Brief summary: The goal of this trial is to determine if an interactive and informative exhibition in the waiting room of a Primary Care Clinic can reduce the use of benzodiazepines in adults. The main question it aims to answer is:

• Does an interactive and informative exhibition reduce the number of participants using benzodiazepines? Researchers will compare benzodiazepine consumption before and after the interactive and informative exhibition implementation at study center.

Participants will receive an informative and interactive exhibition on the risks of chronic benzodiazepine use. A single informative session on the same topic will be conducted for health professionals.


Eligibility criteria: Inclusion Criteria:

* Men and women between 18 and 99 years of age.
* Attended at the Baix-a-Mar Primary Care Center during the study period.

Exclusion Criteria:

* Severe mental health disease
* Displaced patients or those who do not have an assigned doctor at the center.
* Participation in another study involving an experimental intervention during the period of the present study that affects benzodiazepine prescription.

Primary outcomes:
measure: Chronic treatment with benzodiazepines
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Vilanova I La Geltrú
country: Spain
facility: Centro de Salud Vilanova i la Geltrú 3 Baix A Mar
state: Barcelona
Study officials:
affiliation: Centro de Salud Vilanova i la Geltrú 3 Baix A Mar-CSAPG
name: Jordi Milozzi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02474719: Transfer and Ultrafiltration In Peritoneal Dialysis
Official title: Transfer and Ultrafiltration In Peritoneal Dialysis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: End-stage Renal Disease
Keywords: nephrology
extra-renal purification
peritoneal dialysis
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2015-06-18
Enrollment: 17
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The aim of this study is to demonstrate the efficiency of an adapted and "alternate" peritoneal dialysis scheme in terms of sodium extraction and purification compared to an adapted conventional peritoneal dialysis scheme.


Eligibility criteria: Inclusion Criteria:

* Patients hospitalized in the Nephrology department of the Besançon University Hospital
* Patients treated by continuous ambulatory peritoneal dialysis or ambulatory peritoneal dialysis for at least 6 months
* Absence of hospitalization caused by an infection in the month prior to inclusion
* Patients with a ratio (D / P) of the concentration of creatinine in the blood and dialysate between 0.5 and 0.8 on a checkup of less than 1 year.
* No contraindication to the use of hypertonic bag
* Signature of informed consent for participation indicating that the subject has understood the purpose and procedures required by the study and agrees to participate in the study and comply with the requirements and limitations inherent in this study
* Affiliation to a French social security system or beneficiary

Exclusion Criteria:

* Legal incapacity or limited legal capacity
* Patients unlikely to cooperate in the study and/or low cooperation anticipated by the investigator
* Patients without health insurance
* Pregnant women
* Patient being in the exclusion period from another study or planned by the "national register of volunteers"
* Hospitalization caused by an infection in the month prior to inclusion
* Patients with a peritoneal dialysis catheter dysfunction

Primary outcomes:
measure: Intra-dialytic concentrations of different electrolytes (sodium, phosphorus, urea, creatinine, glucose and proteins)
timeFrame: In a maximum of 72 hours after collection
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: Besançon University Hospital, Nephrology Department
state: Franche-Comté
Study officials:
affiliation: Besançon University Hospital, nephrology department
name: Cécile Courivaud, MCU/PH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01719419: The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects
Official title: The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects: A Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Overweight
Lead sponsor: Pennington Biomedical Research Center
Sponsor class: OTHER
First posted: 2012-11-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine if the drug orlistat (Alli, Xenical) decreases the taste for fat in humans.

Detailed description: One screening visit and Testing Visits 1 and 2: Approximately 1-2 hours (Fasting - You will have nothing to eat or drink (except water or medications) after midnight before the test visit.) If you qualify for the study, you will return to Pennington Biomedical Research Center for the test visit

* You will be given a questionnaire to screen for allergies or cold symptoms.
* Women will answer a questionnaire based on their menstrual cycle.
* Before eating, you will be given instructions on how to use the study medication. You will swish about 2 teaspoons of a solution in your mouth for 30 seconds and then spit it out (like mouthwash).
* Just before eating, you will be given another brief questionnaire judging your appetite.
* You will be given the test meal. You will be allowed to eat as much or as little as you like during a 20-minute eating period.
* 30 minutes after starting your meal you will be given the brief questionnaire again to judge your appetite.
* You will return in 1 month to complete test visit 2.

Eligibility criteria: Inclusion Criteria:

* Are a healthy male or female,
* Are between 18 to 70 years of age,
* Have a body mass index between 25-35 kg/m2

Exclusion Criteria:

* Are a female who is pregnant or nursing,
* Are a restrained eater (determined using a questionnaire),
* Have any current illnesses such as an infection,
* Have any serious medical problems including kidney, liver, heart or lung disease,

  * Use medications known to increase appetite,
  * Are taking any medication that has not been on the same dose for at least 30 days,
  * Dislike the test food.

Primary outcomes:
measure: Does orlistat decreases the taste for fatty food intake
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
city: Baton Rouge
country: United States
facility: Pennington Biomedical Research Center
state: Louisiana
Study officials:
References:
Clinical trial NCT01060319: A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
Official title: A Comprehensive Study to Isolate Tumor-initiating Cells From Human Epithelial Malignancies
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Bladder Cancer
Skin Cancers
Bladder (Urothelial, Transitional Cell) Cancer
Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy)
Lead sponsor: Stanford University
Sponsor class: OTHER
Collaborators: name: National Institutes of Health (NIH)
First posted: 2010-02-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues

Brief summary: We hypothesize that all human malignancies harbour a subpopulation of tumor initiating cells/cancer stem cells (CSCs) that drives tumor development and potentially recurrence or metastasis of the disease. The primary aim of this study is to develop strategies for prospective isolation/enrichment of CSCs from human tumors of different tissue origins. In addition, we will characterize the signaling pathways and/or tumor specific antigens that are specific for CSCs, in order to specifically target these CSCs as the endpoint of this study.


Eligibility criteria: Inclusion Criteria:N/A. We will recruit all non-melanoma skin and bladder cancer patients that are recommended for surgical removal of tumor tissues. This includes patients from all ages, gender and ethnicity background. Our sample collection criteria based on the tumor size of individual (e.g. tumor samples will only be collected if it will not affect the pathological diagnosis or treatment procedures of patients). Exclusion Criteria:N/A

Primary outcomes:
measure: Measurement of cancer stem cells (CSCs)
timeFrame: The current study does not include the active involvement of patients. Our study involves the collection of tumor samples from patients after surgical procedures.
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Irving L. Weissman M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03731819: Establishment of Abbreviated Pancreatobiliary MRI Protocol
Official title: Establishment of Abbreviated Pancreatobiliary MRI Using Compressed Sensing Technique for Pancreas Cystic Neoplasm Follow-up
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pancreas Cyst
Intraductal Papillary Mucinous Neoplasm
Keywords: MRI
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2018-11-06
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This study aims to establish abbreviated PB MRI protocol for patients on regular imaging follow-up for pancreas cystic neoplasm.


Eligibility criteria: Inclusion Criteria:

* on follow-up for pancreas intraductal mucinous neoplasm
* OR incidentally detected pancreas cyst (equal to or larger than 1cm)
* AND scheduled for CECT or has CECT within a months
* AND sign informed consent

Exclusion Criteria:

* Any absolute or relative contra-indication for contrast-enhanced MRI
* No pancreas cystic neoplasm
* History of pancreatectomy
* History of any procedure for pancreatic cyst (ablation, aspiration...) in a year
* Hemosiderosis
* Suspicion of acute pancreatitis

Primary outcomes:
measure: Table time of Abbreviated PB MRI
timeFrame: 1 day after PB MRI acquisition
Secondary outcomes:
measure: In room time of Abbreviated PB MRI
timeFrame: 1 day after PB MRI acquisition
measure: Diagnostic confidence
timeFrame: 6 months after participants enrollment
measure: Image quality
timeFrame: 6 months after participants enrollment
measure: Requirement for re-examination
timeFrame: 6 months after participants enrollment
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Jeong Hee Yoon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06945419: A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Official title: A Single-Dose and Multiple-Ascending Dose Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Healthy
Overweight
Obesity
Type 2 Diabetes
Keywords: Oral
Incretin
Weight loss
Overweight
Obesity
Diabetes
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2025-04-25
Enrollment: 165
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.

Participation in Part A of the study will last about 10 weeks and may include up to 6 visits. Participation in Parts B, C, D will last approximately 15 weeks and may include up to 9 visits.


Eligibility criteria: Inclusion Criteria:

* Have no significant body weight change for the 3 months prior to screening

Part A:

* Are considered healthy
* Have a body mass index (BMI) of 22 to 35 kilograms per square meter (kg/m2) at screening

Part B:

* Have a BMI of 27 to 45 kg/m2 at screening

Part C:

* Have a BMI of 25 to 45 kg/m2 at screening

Part D:

* Have type 2 diabetes
* Have hemoglobin A1C (HbA1c) ≥7.0% and ≤10.5% at screening
* Have a BMI of 27 to 45 kg/m2 at screening

Exclusion Criteria:

* Have had an acute cardiovascular condition within the past 6 months prior to screening
* Have liver disease or pancreatitis
* Have used medications for weight loss within the 3 months prior to screening

Parts A, B, C:

* Have any form of diabetes

Part D:

* Have type 1 diabetes

Primary outcomes:
measure: Number of Participants with One or More Serious Adverse Events (SAE) Considered by the Investigator to be Related to Study Drug Administration
timeFrame: Baseline through Week 15
Secondary outcomes:
measure: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY4086940
timeFrame: Predose up to Day 63
measure: PK: Area Under the Concentration Versus Time Curve (AUC) of LY4086940
timeFrame: Predose up to Day 63
Other outcomes:
Locations:
city: Daytona Beach
country: United States
facility: Fortrea Clinical Research Unit
state: Florida
city: Dallas
country: United States
facility: Fortrea Clinical Research Unit
state: Texas
city: San Antonio
country: United States
facility: Endeavor Clinical Trials
state: Texas
city: Singapore
country: Singapore
facility: Lilly Centre for Clinical Pharmacology
Study officials:
affiliation: Eli Lilly and Company
name: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
role: STUDY_DIRECTOR
References:
Clinical trial NCT00657319: Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
Official title: Glycaemic Control and Quality of Care in Type 2 Diabetes on NovoMix® 30 Previously Treated With Mixtard® Insulins
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2008-04-14
Enrollment: 3495
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult with type 2 diabetes mellitus on premix insulin treatment.

Brief summary: This observational study is conducted in Europe. The objective of this retrospective observational cohort analysis is to assess the changes of glycaemic control and quality of care in those Type 2 diabetic patients who were previously treated with Mixtard® insulins after 6 months of their switch to analog premix insulin NovoMix® 30 therapy.


Eligibility criteria: Inclusion Criteria:

* Subjects diagnosed with type 2 diabetes previously treated with BHI for at least 12 months
* Analogue premix administration for the last 6 months

Exclusion Criteria:

* Known or suspected allergy to insulin aspart
* Newly diagnosed diabetes

Primary outcomes:
measure: HbA1C
timeFrame: 6 months
Secondary outcomes:
measure: General conditions (reason of switch, BMI, selected laboratory parameters, quality of care)
timeFrame: 6 months
Other outcomes:
Locations:
city: Budapest
country: Hungary
facility: Novo Nordisk Investigational Site
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
citation: Gerö L. Improvement in metabolic control in type 2 diabetic patients after switching from biphasic human insulin (BHI) to biphasic insulin aspart 30/70 (BIAsp 30): An observational study in Hungary. ADA American Diabetes Association 2009; Country: USA City: New Orleans
Clinical trial NCT02347319: To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease
Official title: A Double-Blind, Randomized, Multicenter Trial Examining the Efficacy of Biphenyl Dimethyl Dicarboxylate Combined With Garlic Oil in Patients With Transaminase Elevated Chronic Liver Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Chronic Liver Disease
Lead sponsor: PharmaKing
Sponsor class: INDUSTRY
First posted: 2015-01-27
Enrollment: 262
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Purpose

- To evaluate the efficacy of Biphenyl dimethyl dicarboxylate(DDB)/Garlic Oil in patients with elevated transaminase chronic liver disease.

Detailed description: Biphenyl dimethyl dicarboxylate (DDB) combined with garlic oil (pennel) has been used to treat chronic liver disease. A randomized, double-blind, active- and placebo-controlled clinical trial was conducted to investigate the efficacy, safety and quality of life in chronic liver disease patients.

Eligibility criteria: Inclusion Criteria:

* Patients over 20years of age
* Patients with more 60 ALT in screening period.
* To evaluate ALT and AST at least three months.
* Serum Transaminase abnormal(before 6months), chronic liver disease or fatty liver, liver disease medical treatment at more than 30days
* Women of childbearing age get her consent for contraception, pregnancy urine test result negative.

Exclusion Criteria:

* ALT\>10UNL on screening period.
* Current treatment on another clinical trial
* Pregnancy or breastfeeding

Primary outcomes:
measure: Normalized rate in serum ALT
timeFrame: 12 weeks
Secondary outcomes:
measure: ALT
timeFrame: 8, 12 weeks
measure: AST
timeFrame: 8, 12 weeks
measure: γ-GTP
timeFrame: 8, 12 weeks
measure: AST/ALT ratio
timeFrame: 8, 12 weeks
measure: ALP
timeFrame: 8, 12 weeks
measure: Albumin
timeFrame: 8, 12 weeks
measure: Total Bilirubin
timeFrame: 8, 12 weeks
measure: The assessment of health-related quality of life
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Bucheon
country: Korea, Republic of
facility: The catholic university of korea, Bucheon ST. Mary's Hosipital
state: Gyeonggi-do
Study officials:
References:
Clinical trial NCT06402019: Dexmedetomidine Infusion Impact on Chronic Pain Patients
Official title: Repeated Dexmedetomidine Infusion is a Two-shot Weapon for Pain and Pain-induced Mood Disorders in Chronic Pain Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Pain
Lead sponsor: Benha University
Sponsor class: OTHER
First posted: 2024-05-07
Enrollment: 100
Sex: ALL
Minimum age (years): 30
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Chronic pain (CP) was defined as pain experienced daily or on most days and induced restriction of at least one activity. CP is one of the commonest complaints confronted in outpatient clinics and constitutes a challenge for all medical provisions. CP is a multifaceted condition; postoperative CP is frequently encountered in clinical practice and may be of debilitating severity leading to worse quality of life (QOL) especially CP with a neuropathic component as post-mastectomy pain syndrome and post-amputation pain and chronic post-sternotomy pain that seriously impacts patients' QOL and affects patient recovery till 12 months after cardiac surgery. Chronic musculoskeletal pain as defined by the International Pain Association is the persistent or recurrent pain involving spine, bones, joints, and/or musculo-soft tissue.

Chronic pain was considered as a long-lasting stressor that might induce disordered mood varying between depression and anxiety with consequent challenge of this combination on treatment outcomes and consumption of health resources. This necessitated psychological screening of CP patient to identify and manage patients with disordered mood to improve CP treatment outcomes.


Eligibility criteria: Inclusion Criteria:

* Patients with multiple-level spinal canal stenosis who refused surgical management.

Exclusion Criteria:

* Patients with other causes for CP;
* maintained on opioid analgesia;
* had cardiac lesions;
* maintained on antihypertensive therapy;
* hepatic impairment;
* Patients can't attend the clinic to complete the course of Dexmedetomidine infusion sessions.

Primary outcomes:
measure: The extent of reduction of consumed analgesics
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Benha university
state: Qalyoubia
Study officials:
References: